Status:

COMPLETED

A PK/PD Genetic Variation Treatment Algorithm Versus Treatment As Usual for Adolescent Management Of Depression

Lead Sponsor:

Mayo Clinic

Conditions:

Depression

Eligibility:

All Genders

13-18 years

Phase:

NA

Brief Summary

The overall goal of this investigator-initiated trial is to evaluate the impact of platform algorithm products designed to rapidly identify pharmacokinetic (PK) and/or pharmacodynamic (PD) genomic var...

Detailed Description

Treatment seeking adolescent patients with a moderate to severe major depressive episode defined as a 40 or greater on Childhood Depression Rating Scale-Revised (CDRS-R) will be invited to participate...

Eligibility Criteria

Inclusion

  • Age 13-18, male or female, any race/ethnicity
  • Treating clinician, patient, and family feel that pharmacotherapy is indicated as part of a comprehensive treatment plan.
  • Major depressive episode diagnosis or bipolar disorder based on KSADS-PL semi-structured psychiatric interview with a severity criteria-40 or greater on Childhood Depression Rating Scale-Revised (CDRS-R)
  • Ability to provide informed consent

Exclusion

  • Inability to speak English
  • Inability or lack of willingness to provide informed consent and assent.
  • Axis I diagnoses: Autism Spectrum Disorder, Anorexia Nervosa, Schizophreniform, and Schizophrenia.
  • Psychotropic medication change (including dosage) between screening \& randomization visits.
  • Patients who meet DSM 5 criteria for any significant current substance use disorder other than nicotine, caffeine, or cannabis. Must have at least early, partial or full, remission X 3 months
  • Serious suicidal risk and/or in need of immediate hospitalization as judged by the investigator.
  • Significant unstable medical condition.
  • Anticipated inability to attend scheduled study visits.
  • Patients who in the judgment of the Investigator may be unreliable or uncooperative with the evaluation procedure outlined in this protocol.
  • Cytochrome (CYP) \& serotonin transporter genomic testing within 5 years.

Key Trial Info

Start Date :

February 1 2015

Trial Type :

INTERVENTIONAL

Allocation :

ACTUAL

End Date :

February 6 2019

Estimated Enrollment :

179 Patients enrolled

Trial Details

Trial ID

NCT02286440

Start Date

February 1 2015

End Date

February 6 2019

Last Update

June 16 2020

Active Locations (2)

Enter a location and click search to find clinical trials sorted by distance.

Page 1 of 1 (2 locations)

1

Mayo Clinic in Rochester

Rochester, Minnesota, United States, 55905

2

Mayo Clinic

Rochester, Minnesota, United States, 55905